Gentler myeloma treatment shows promise for frail patients

NCT ID NCT05911321

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—isatuximab, pomalidomide, and dexamethasone—at lower doses than usual. It includes 6 patients with multiple myeloma that has returned or not responded to treatment, who are also vulnerable due to age or other health problems. The goal is to see if this gentler approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, pomalidomide, and dexamethasone
What this could lead to: If this works, it could offer a safer treatment option for multiple myeloma patients who are older or have other health issues.
What could go wrong: This is a very small early-phase trial with only 6 participants, so results may not apply broadly. Lower doses might also be less effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING CO-MORBIDITY MULTIPLE MYELOMA REFRACTORY RELAPSE

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States
Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.